BioSpace News Archive

Alzamend Neuro, Inc. today announced that it has submitted a Pre-IND (investigational new drug) meeting request for AL001 and supporting briefing documents to the U.S. Food and Drug Administration (“FDA”) for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder (“PTSD”).

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced that it will present new clinical pharmacology data at the 24th European Congress of Endocrinology (ECE 2022) on its lead candidate, SPI-62, an HSD-1 inhibitor.

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary microneedle patch system.

EyePoint Pharmaceuticals, Inc. announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C Wainwright Global Healthcare Investment Conference.

BridgeBio Pharma, Inc. announced that members of the management team will participate in the following upcoming investor conferences:

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the addition of Shepherd Center in Atlanta, Georgia to its Therapeutic Experience Program.

StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2022, and provided an update on its business progress.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four data presentations for AUSTEDO® (deutetrabenazine) tablets and TV-46000/mdc-IRM.